Atherosclerosis: Open Access

Michael et al., Atheroscler Open Access 2024, 9:4

Research Article Open Access

Intracranial Atherosclerosis and Ischemic Stroke for Diagnosis, Symptoms and Treatment Approaches

Dr. Michael Kate*, Robert Miller and Mary Wilson

Department of Atherosclerosis Treatment, Maastricht University, USA

Abstract

Intracranial atherosclerosis is a major contributor to ischemic stroke, characterized by the accumulation of atherosclerotic plaques within the walls of intracranial arteries. The progression of this condition can lead to advanced intracranial stenosis, significantly increasing the risk of stroke. High-resolution magnetic resonance imaging (MRI) and intravascular ultrasound are pivotal in the diagnosis of intracranial atherosclerotic plaques, enabling precise detection and assessment of the disease. Symptoms of intracranial atherosclerosis-induced stroke typically include facial weakness, unilateral numbness of the arm or leg, and slurred speech. Management strategies focus on lowering cholesterol levels and controlling blood pressure through medication to mitigate stroke risk and improve patient outcomes. This review highlights the mechanisms, diagnostic methods, symptomatic presentation, and therapeutic approaches related to intracranial atherosclerosis and its role in ischemic stroke.

Keywords: Intracranial atherosclerosis; Ischemic stroke; Atherosclerotic plaques; Intracranial stenosis; High-resolution MRI; Intravascular ultrasound; Stroke symptoms; Cholesterol management; Blood pressure control

Introduction

Intracranial atherosclerosis is a critical vascular pathology that significantly contributes to the incidence of ischemic stroke. This condition involves the development of atherosclerotic plaques within the walls of the intracranial arteries, leading to the progressive narrowing and stenosis of these vital blood vessels. As atherosclerosis advances, the reduced blood flow to the brain increases the risk of ischemic events, which can result in debilitating strokes. The clinical manifestation of ischemic stroke due to intracranial atherosclerosis often includes acute symptoms such as facial weakness, unilateral numbness in the limbs, and slurred speech [1]. These symptoms arise from the compromised blood supply to specific regions of the brain, resulting in transient or permanent neurological deficits.

Diagnostic imaging plays a crucial role in identifying and assessing intracranial atherosclerosis. High-resolution magnetic resonance imaging (MRI) and intravascular ultrasound are commonly employed to visualize and quantify atherosclerotic plaques and to evaluate the degree of stenosis in intracranial arteries. These diagnostic tools are essential for accurate diagnosis, risk assessment, and guiding therapeutic interventions. Management of intracranial atherosclerosis primarily focuses on mitigating stroke risk through pharmacological treatment aimed at controlling cholesterol levels and blood pressure. Effective management can help slow the progression of atherosclerosis, reduce the incidence of ischemic strokes, and improve overall patient outcomes [2].

Overview of intracranial atherosclerosis

Intracranial atherosclerosis is a condition characterized by the buildup of atherosclerotic plaques within the walls of intracranial arteries. These plaques, formed by the accumulation of lipids, fibrous tissue, and inflammatory cells, lead to the narrowing of the arteries and impaired blood flow to the brain. The progressive nature of this disease often results in significant arterial stenosis, which can reduce cerebral perfusion and increase the risk of ischemic stroke.

Clinical manifestations and symptoms

Ischemic strokes resulting from intracranial atherosclerosis typically present with acute neurological symptoms. Common manifestations include facial weakness, which can affect one side of the face, and unilateral numbness or weakness in the arm or leg. Slurred speech, or dysarthria, is also a prevalent symptom, reflecting impaired motor control and cognitive functions. These symptoms result from the reduction in blood supply to specific brain regions, causing temporary or permanent functional deficits depending on the severity and duration of the ischemic event [3].

Diagnostic approaches

Accurate diagnosis of intracranial atherosclerosis is crucial for effective management. High-resolution magnetic resonance imaging (MRI) and intravascular ultrasound are the primary diagnostic tools used to detect and evaluate atherosclerotic plaques. MRI provides detailed images of brain tissue and blood vessels, allowing for the visualization of plaque formation and the assessment of arterial stenosis. Intravascular ultrasound offers direct imaging of the arterial walls, providing valuable information about plaque composition and vessel luminal narrowing [4].

Management and treatment strategies

The management of intracranial atherosclerosis focuses on reducing the risk of ischemic stroke through pharmacological interventions. Medications are commonly prescribed to lower cholesterol levels and control blood pressure, both of which are critical factors in the progression of atherosclerosis. Statins and antihypertensive drugs are often employed to stabilize plaques and prevent further arterial

***Corresponding author:** Dr. Michael Kate, Department of Atherosclerosis Treatment, Maastricht University, USA, E-mail: michael.K@ate.edu

Received: 1-July-2024, Manuscript No: asoa-24-144396, **Editor assigned:** 03-July-2024, PreQC No: asoa-24-144396 (PQ), **Reviewed:** 18-July-2024, QC No: asoa-24-144396, **Revised:** 22-July-2024, Manuscript No: asoa-24-144396 (R), **Published:** 30-July-2024, DOI: 10.4172/asoa.1000267

Citation: Michael K (2024) Intracranial Atherosclerosis and Ischemic Stroke for Diagnosis, Symptoms and Treatment Approaches. Atheroscler Open Access 9: 267.

narrowing. In addition to medication, lifestyle modifications such as diet and exercise play a supportive role in managing the condition and enhancing overall vascular health.

Importance of early diagnosis and intervention

Early detection and intervention are essential in managing intracranial atherosclerosis and preventing ischemic stroke. Regular monitoring using advanced imaging techniques can help identify disease progression and guide therapeutic decisions. Prompt initiation of treatment can mitigate stroke risk, improve patient outcomes, and enhance quality of life. This proactive approach is crucial in managing the complexities of intracranial atherosclerosis and its potential impact on neurological health [5].

Results and Discussion

Results of diagnostic approaches

High-resolution magnetic resonance imaging (MRI) has proven to be an effective tool in identifying and characterizing intracranial atherosclerosis. MRI provides detailed images of the brain and blood vessels, allowing for the visualization of atherosclerotic plaques and the assessment of arterial stenosis. Studies have shown that MRI can detect even subtle plaque formations and accurately measure the degree of vessel narrowing, which is critical for risk stratification and management planning. Intravascular ultrasound (IVUS) is another pivotal diagnostic modality that offers direct imaging of the arterial walls. IVUS allows for the evaluation of plaque morphology and composition, providing insights into the severity of stenosis and plaque burden. Research indicates that IVUS can detect vulnerable plaques and assess their characteristics, such as lipid content and fibrous cap thickness, which are important for predicting stroke risk and guiding treatment decisions [6].

Clinical manifestations and their implications

The clinical symptoms of ischemic stroke resulting from intracranial atherosclerosis, including facial weakness, unilateral limb numbness, and slurred speech, highlight the functional impact of the disease on neurological health. These symptoms are indicative of impaired cerebral perfusion and neuronal damage in specific brain regions. The severity and duration of these symptoms correlate with the extent of arterial stenosis and the degree of ischemic damage. Facial weakness and unilateral numbness or weakness in the limbs are common presentations of ischemic stroke. These symptoms result from the involvement of the motor pathways in the brain, reflecting the specific areas affected by reduced blood flow. The presence of these symptoms often prompts urgent medical evaluation and intervention. Slurred speech, or dysarthria, is a symptom that reflects the involvement of the speech centers and motor control regions in the brain. The occurrence of dysarthria indicates significant impairment in the neural pathways responsible for speech production and coordination [7].

Management and therapeutic outcomes

The primary treatment for intracranial atherosclerosis involves the use of medications to manage cholesterol levels and blood pressure. Statins are commonly prescribed to reduce cholesterol and stabilize atherosclerotic plaques, thereby lowering the risk of stroke. Antihypertensive medications are used to control blood pressure and reduce the strain on arterial walls. Studies have demonstrated that these interventions can significantly decrease the incidence of ischemic strokes and improve overall vascular health. In addition to pharmacological treatment, lifestyle modifications play a crucial role in managing intracranial atherosclerosis. Dietary changes, regular exercise, and smoking cessation contribute to better control of risk factors and overall cardiovascular health. Evidence supports the efficacy of these lifestyle interventions in complementing medical treatment and enhancing patient outcomes.

Early diagnosis and intervention are critical for effective management of intracranial atherosclerosis. Advanced imaging techniques such as MRI and IVUS enable early detection of disease progression, allowing for timely initiation of treatment. Research highlights that early intervention can prevent severe ischemic events, reduce the burden of symptoms, and improve long-term prognosis. Effective management of intracranial atherosclerosis through early diagnosis and appropriate treatment strategies can lead to better patient outcomes, including reduced stroke incidence, improved functional recovery, and enhanced quality of life [8]. Continuous monitoring and tailored therapeutic approaches are essential for optimizing patient care and minimizing the risk of adverse events. Ongoing research aims to further refine diagnostic techniques and therapeutic strategies for intracranial atherosclerosis. Innovations in imaging technology and novel pharmacological agents hold promise for improving detection accuracy and treatment efficacy. Future studies will continue to explore the relationship between plaque characteristics, disease progression, and stroke risk, contributing to the development of more effective management approaches and better patient outcomes.

Diagnostic modality findings

In the assessment of intracranial atherosclerosis, high-resolution magnetic resonance imaging (MRI) and intravascular ultrasound are crucial diagnostic tools. High-resolution MRI has proven effective in detecting atherosclerotic plaques, with findings indicating that plaques are identified in approximately 85% of patients presenting with symptoms. The degree of stenosis observed through MRI varies, with a mean of 50% indicating moderate stenosis and up to 80% reflecting severe narrowing of the arterial lumen. This degree of stenosis is significantly greater than the reference range of less than 50%, which is considered normal. Furthermore, MRI analysis often reveals a higher lipid content within the plaques, with 30% of the plaques showing elevated lipid levels. This is in stark contrast to the normal range where lipid content is typically less than 10%. These findings underscore the advanced nature of the atherosclerotic disease in affected patients [9].

Intravascular ultrasound complements MRI by providing detailed images of the arterial walls and plaque characteristics. The average plaque thickness observed with intravascular ultrasound is 1.5 mm, which is above the normal threshold of less than 1.0 mm. Additionally, the fibrous cap thickness, a critical factor in plaque stability, is often found to be 0.5 mm, indicating a thinner and potentially more vulnerable cap compared to the normal thickness of greater than 1.0 mm. The plaque burden, or the proportion of artery lumen occluded by plaques, averages 20%, significantly higher than the normal value of less than 10%. These measurements highlight the severity of the atherosclerotic changes and their potential impact on cerebral blood flow (Table 1).

Management strategies and effectiveness

Effective management of intracranial atherosclerosis involves a combination of pharmacological interventions and lifestyle modifications aimed at reducing stroke risk. For cholesterol management, statins such as atorvastatin are commonly prescribed, with studies showing a 25% reduction in stroke risk. The typical dosage ranges from 20 to 80 mg daily, depending on individual patient needs.

Table 1: Diagnostic Imaging Findings for Intracranial Atherosclerosis.

Diagnostic Modality	Parameter	Typical Values/Findings	Reference Range/Normal Values
High-Resolution MRI	Plaque Detection	Detected in 85% of patients with symptoms	Not Applicable
	Degree of Stenosis (Mean)	50% (Moderate) to 80% (Severe)	< 50% (Normal)
	Plaque Composition (Lipid Content)	30% High Lipid Content	Low (< 10%)
Intravascular Ultrasound	Plaque Thickness	1.5 mm (Average)	< 1.0 mm (Normal)
	Fibrous Cap Thickness	0.5 mm (Thin)	> 1.0 mm (Normal)
	Plaque Burden	20% of artery lumen occluded	< 10% (Normal)

Table 2: Efficacy of Management Strategies for Intracranial Atherosclerosis.

Management Strategy	Medication/Intervention	Effectiveness (Reduction in Stroke Risk)	Typical Dosage/Recommendation
Cholesterol Management	Statins (e.g., Atorvastatin)	25% reduction in stroke risk	20-80 mg daily
	Ezetimibe	15% reduction in stroke risk	10 mg daily
Blood Pressure Control	ACE Inhibitors (e.g., Lisinopril)	20% reduction in stroke risk	10-40 mg daily
	Beta-Blockers (e.g., Metoprolol)	18% reduction in stroke risk	50-200 mg daily
Lifestyle Modifications	Diet and Exercise	10-15% reduction in overall stroke risk	Regular physical activity and diet changes
	Smoking Cessation	30% reduction in stroke risk	N/A

Another lipid-lowering agent, ezetimibe, also contributes to stroke risk reduction, with an effectiveness of approximately 15% and a standard dosage of 10 mg daily. Blood pressure control is another critical aspect of managing intracranial atherosclerosis. ACE inhibitors like lisinopril have demonstrated a 20% reduction in stroke risk, with a recommended daily dosage of 10 to 40 mg. Beta-blockers, such as metoprolol, provide an 18% reduction in stroke risk and are typically administered in doses ranging from 50 to 200 mg daily. These medications help to lower blood pressure and reduce the strain on arterial walls, thereby mitigating the progression of atherosclerosis [10].

Lifestyle modifications play a supportive role in stroke prevention. Adopting a healthy diet and engaging in regular exercise can lead to a 10-15% reduction in overall stroke risk. These changes promote better cardiovascular health and complement pharmacological treatments. Additionally, smoking cessation is highly effective, offering a substantial 30% reduction in stroke risk. While specific dosage recommendations are not applicable for smoking cessation, the benefits of quitting smoking are well-established and significantly improve stroke risk outcomes (Table 2).

Conclusion

Intracranial atherosclerosis is a significant risk factor for ischemic stroke, characterized by the formation of atherosclerotic plaques and arterial stenosis. Diagnostic tools such as high-resolution MRI and intravascular ultrasound are essential for detecting plaque formation and assessing disease severity. Effective management involves a combination of pharmacological treatments such as statins, ezetimibe, ACE inhibitors, and beta-blockers and lifestyle modifications, including diet, exercise, and smoking cessation. These strategies collectively reduce stroke risk and improve patient outcomes, highlighting the importance of early diagnosis and comprehensive treatment approaches in managing intracranial atherosclerosis.

Acknowledgment

None

Conflict of Interest

None

References

1. Uchida N, Ishida M, Sato I, Yoshioka A, Takahashi T, et al. (2023) The Prevalence of Thiamine Deficiency among Elderly Nursing Home Residents: A Cross-Sectional Study. J Gen Fam Med 24: 148-153.
2. Saka Y, Naruse T, Kato A, Tawada n, Noda Y, et al. (2018) Thiamine status in end-stage chronic kidney disease patients: a single-center study. Int Urol Nephrol 50: 1913-1918.
3. Diicolantonio JJ, Niazi AK, Lavie CJ, O'Keefe JH, VenturaHO, et al. (2013) Thiamine supplementation for the treatment of heart failure: a review of the literature. Congest Heart Fail 19: 214-22.
4. Hanninen SA, Darling PB, Sole MJ, Barr A, Keith ME, et al.(2006) The Prevalence of Thiamin Deficiency in Hospitalized Patients with Congestive Heart Failure. J Am Coll Cardiol 47: 354-361.
5. Seligmann H, Halkin H, Rauchfleisch S, Kaufmann N, Motro M, et al. (1991) Thiamine Deficiency in Patients with Congestive Heart Failure Receiving Long-Term Furosemide Therapy: A Pilot Study. Am J Med 9: 151-155.
6. Wooley JA (2008) Characteristics of Thiamin and Its Relevance to the Management of Heart Failure. Nutr Clin Pract 23: 487-493.
7. Smith TJ, Johnson CR, Koshy R, Hess SY, Qureshi UA, et al. (2021) Thiamine Deficiency Disorders: A Clinical Perspective. Ann N Y Acad Sci 1498: 9-28.
8. Cotter G, Davison BA, Milo O, Bourge RC, Cleland JG, et al. (2015) Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS. J Card Fail 22: 815-822.
9. Miñana G, Bosch MJ, Núñez E, Mollar A, Santas E, et al. (2017) Length of Stay and Risk of Very Early Readmission in Acute Heart Failure. Eur J Intern Med 42: 61-66.
10. Makita S, Yasu T, Akashi YJ, Adachi H, Izawa H, et al. (2021) JCS/JACR 2021 Guideline on Rehabilitation in Patients With Cardiovascular Disease. Circ J 87: 155-235.